Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406677 · ClinicalTrials.gov registry record · Phase 4
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
A Phase 4 study of Cost Sharing, Acute Coronary Syndrome, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 11,001
- Enrollment target
- 20
- Study locations
NCT02406677: Completed Phase 4 study of Cost Sharing, Acute Coronary Syndrome, sponsored by AstraZeneca.
NCT02406677 is a Phase 4 study of Cost Sharing, Acute Coronary Syndrome that has completed, run by AstraZeneca. The registered enrollment target is 11,001 participants, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (2028% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02406677, a Phase 4 study of Cost Sharing, Acute Coronary Syndrome, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11,001 participants
- Enrollment target
- 20
- Study locations
Study Summary
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess the impact of copayment reduction by equalizing the copayment of clopidogrel and ticagrelor. ARTEMIS will assess prescribing patterns, patient medication adherence, and clinical outcomes up to one year. We hypothesize that reducing out--of--pocket cost for P2Y12 receptor inhibitor will lead to improved adherence. Additionally, copayment reduction of both generic and brand antiplatelet agents may lead to a reduction in MACE risk. This is in part due to greater adherence to an evidence--based secondary prevention medication. Additionally the reduction in MACE may reflect greater selection of a more potent antiplatelet agent that has been shown to reduce MACE in randomized clinical trials, as provider choice of antiplatelet therapy will be primarily driven by risk- benefit assessment rather than the cost burden to the patient.
Primary Outcome
To determine if patient copayment reduction leads to lower risk of MACE (composite of death, MI, and stroke) at 1 year after discharge.
Conditions Studied
Interventions
- OTHER Study voucher card
Study Locations (20)
California
- Research Site - Escondido
- Research Site - Huntington Beach
- Research Site - Loma Linda
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Northridge
- Research Site - Pasadena
- Research Site - Riverside
Alabama
- Research Site - Birmingham
- Research Site - Huntsville
- Research Site - Mobile
- Research Site - Mobile
Arkansas
- Research Site - Fayetteville
- Research Site - Fort Smith
- Research Site - Jonesboro
- Research Site - Little Rock
Arizona
- Research Site - Cottonwood
- Research Site - Flagstaff
- Research Site - Phoenix
Alaska
- Research Site - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,001 participants |
| Start Date | 2015-06-05 |
| Est. Completion | 2017-10-23 |
| Phase | Phase 4 |
What the finished NCT02406677 record still lists
NCT02406677 is an interventional study that assigns participants to a tested intervention. Its 11,001 participants enrollment target places it among the larger protocols in the corpus, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (2028% higher).
The record links to 1 condition, with Cost Sharing, Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Study voucher card is the first listed.
NCT02406677 names 20 study sites across 5 states, led by California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT02406677 about?
NCT02406677 is a clinical study titled "Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study". Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes. The ARTEMIS trial is a practical multicenter, cluster- randomized clinical trial that will assess t...
What is the current status of trial NCT02406677?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11,001 participants. The study started on 2015-06-05. Estimated completion is 2017-10-23.
What conditions does trial NCT02406677 study?
This clinical trial studies the following conditions: Cost Sharing, Acute Coronary Syndrome.
What interventions are being tested in trial NCT02406677?
The interventions under investigation include: Study voucher card (OTHER).
Who is sponsoring clinical trial NCT02406677?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02406677 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02406677's enrollment target sits among peer trials
11,001 7th of 2000 higher than 1,994 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI